JAK1/3 inhibitors (Bristol-Myers Squibb)

N/A

Report date: 2025/01/26 15:56:49
NME

Base Information

Drug NameJAK1/3 inhibitors (Bristol-Myers Squibb)
Drug Alias NameBMT-1438
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK3
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A